Browse by Track

(A01) Disparities in Guideline-Recommended Pharmacotherapy for Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and Sex: A Nationally Representative Cross-Sectional Analysis of Adults in the United States

(A02) Ethnic differences in the indirect impacts of the COVID-19 pandemic on hospitalisations for non-COVID conditions in England: An observational cohort study using OpenSAFELY

(A03) Ethnicity differences in risk of cardiovascular events in COVID-19: an England-wide population analysis

(A04) Representation of patients of minority race and ethnicity in real-world databases and tumor registries of patients with breast cancer

(A05) Social Determinants of Health and Disparities in T2DM Severity in the United States

(A06) The Impact of Contextual-Level Social Determinants of Health on Heart Failure Readmission and Mortality in Patients Hospitalized for Heart Failure

(A07) The Use of Computational Phenotypes Within Electronic Healthcare Data to Identify Transgender People: A Narrative Review

(A08) Using Real-World Data to Support Clinical Trial Diversity and Inclusion Strategies: A Case Study of Cancer of the Cervix

(A09) Clinical validation studies for SARS-CoV-2 diagnostic tests in a real-world setting

(A10) Continuous Glucose Monitoring in Diabetes Patients with Cognitive Impairment

(A11) COVID-RED: A randomized trial demonstrating earlier COVID-19 remote detection using wearable technology and artificial intelligence

(A13) Robot-assisted Surgery and Racial and Ethnic Disparities in Post-prostatectomy Outcomes among Prostate Cancer Patients

(A14) Systematic Review and Meta-analysis of Clinical Outcomes of Bone Grafting/Reconstruction Following Segmental Long Bone Defects Treated by Induced Membrane Technique

(A15) Temporal Trends in Using Catheter Ablation as First-Line Therapy in Patients Diagnosed with Paroxysmal Atrial Fibrillation in the United States

(A16) Trends in the Cost of Total Knee Arthroplasty — a US Hospital Database Analysis, 2000 – 2021

(A17) Antidepressant Utilization Before and After Initiation of Prenatal Care Among Commercially Insured Pregnant Women in the United States

(A18) Maternal Exposure of Benzodiazepine Receptor Agonists and Increased Risk of Neurodevelopmental Disorders in Offspring in Taiwan

(A19) Maternal Prescribed Opioid Analgesic Use During Pregnancy and Associations with Neurodevelopmental Disorders in Offspring

(A20) Social and Demographic Disparities in the Adherence to Antihypertensive Medication During Pregnancy

(A21) Topical azole treatments during pregnancy: Are there risks for the pregnant mother and the fetus? A comparative study in the EFEMERIS database

(A22) Utilization of antihypertensives before, during, and after pregnancy

(A23) Utilization patterns of Antidepressants in pregnant women: An interrupted time series analysis

(A24) Validation study of an ASA prophylaxis variable for preeclampsia prevention

(A25) An Observational Post Approval Safety Study of Etanercept and Methotrexate in Treatment of Juvenile Idiopathic Arthritis (JIA) using the German Biologics JIA Registry (BIKER)

(A26) Antiepileptic Drug Use in Children Beyond Epilepsy: A Population-Based Longitudinal Study

(A27) Incidence of COVID-19 disease severity in a cohort of 4.4 million Italian and Spanish children from 6 healthcare databases

(A28) Metrics of Antibiotic Use in Neonatal Intensive Care Units

(A29) Natural History of RSV Infection in Outpatient Pediatric Patients in the United States

(A30) Overview of Global Real World Data Sources for Pediatric Pharmacoepidemiologic Research

(A31) Population-Based Incidence of Influenza-Associated Serious Neuropsychiatric Events

(A32) Utilization of beta-blockers among the pediatric population in the United States: a study in the FDA’s Sentinel System from 2008 to 2022

(A33) A Retrospective Cohort Study Using Administrative Claims to Compare the Incidence of Eosinophilic Granulomatosis with Polyangiitis in Patients with and without Asthma, Stratified by Asthma Severity

(A34) Analgesics Utilization in Danish Cystic Fibrosis Patients

(A35) Characteristics, Disease Burden, and Preliminary Outcomes of Patients with Myasthenia Gravis in Real-World Treatment Settings Across the United States

(A36) Diagnosed Prevalence of Hypophosphatasia in the United States: a Real World Analysis of Electronic Health Records

(A38) Epidemiology of rare kidney diseases in the United Kingdom using a large rare renal registry

(A39) Federated Hospital Electronic Health Record Networks for Trial Feasibility Assessments in Rare Diseases: A Pilot Study in Neurofibromatosis Type 1

(A40) Identifying Generalized Pustular Psoriasis Flares Using Natural Language Processing of Unstructured Clinical Notes and Structured Procedure Codes

(A41) Cardiovascular Risk and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors: A Nationwide Comparative Effectiveness Research Study

(A42) Case studies of FDA recently approved product applications using real-world evidence - What are the attributes of studies that support effectiveness determinations?

(A43) Decreased Venous Thromboembolic Risk of Estradiol Valerate/Dienogest COCs Compared to First-line COCs Containing Ethinyl Estradiol/Levonorgestrel: Pooled Analysis in a Large Real-World User Population

(A44) Lessons Learned from the Development of Machine Learning Models to Estimate Validated Measures Using Real-World Data for Four Chronic Conditions

(A45) Machine Learning to Predict Successful Treatment of Atrial Fibrillation by Medical Devices Using Digital Data Linked to EHR Data

(A46) Progression to ESRD Among White, Black and Hispanic Diabetic Kidney Disease Patients: Real-World Evidence from Multiple Linked Claims Databases

(A47) Use and contribution of registries in registry-based randomized clinical trials: a review

(A48) Use of Antibiotics in the ‘Watch’ category of the WHO AWaRe classification in Europe: a DARWIN-EU® multinational network cohort study (EUPAS103381)

(A49) Carditis risk following covid-19 vaccination with mRNA (BNT162b2) or inactivated (CoronaVac): a self-controlled cases series and a case-control study

(A50) Characterization of U.S. Adults Aged 18–64 Years Vaccinated Against Mpox within the Food and Drug Administration Biologics Effectiveness and Safety (BEST) Initiative

(A51) Evaluation of the risk of potential adverse events following bivalent COVID-19 vaccines in Veteran patients

(A52) Post-marketing surveillance of human papillomavirus (HPV)-related high-grade cervical disease in a cohort of Chinese women who received the 9-valent HPV vaccine

(A53) Safety monitoring of COVID-19 vaccines in multiple European countries: initial results from the COVID-19 Vaccine Monitor (CVM)

(A54) The effect of sex on the incidence, latency, duration and burden of adverse events following influenza vaccination

(A55) The importance of contextualising overall measures of COVID-19 vaccine effectiveness: the COVIDRIVE-AstraZeneca experience

(A56) Vaccine patterns among older adults diagnosed with Guillain-Barré Syndrome and matched counterparts with Medicare insurance, 2006-2019

(B01) Adherence and persistence to cardiovascular medicines in Australia among people initiating therapy in 2018

(B02) Adherence to hypoglycemic medications among pregnant patients with gestational diabetes

(B03) Cost-Related Nonadherence Among Adults with Multiple Chronic Conditions in the US from 2013 to 2021

(B04) Direct Medical Cost Associated with Antiplatelet Non-persistence in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention

(B05) Effectiveness of Medication Therapy Management in Older Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

(B06) Evaluate Medication Adherence Classes using Latent Mixed Model

(B07) Exploring Real-life Persistence with Denosumab (Prolia®): A 7-year-follow-up Study In Spain

(B08) Older adults’ adherence to medications and willingness to deprescribe: A sub-study of a randomized clinical trial

(B09) A Hospital-Based Cohort Study on Drug-Related Problems Associated with High-Risk Medications Amongst Special Populations

(B10) Comparison of common protocol vs. common data model and the issues of analytic inconsistency for a multi-database pharmacoepidemiologic study

(B11) Comparisons of non-vitamin K antagonist oral anticoagulants and warfarin for incident depressive disorders in patients with atrial fibrillation: A nationwide cohort study using target trial emulation framework

(B12) Effect of Bisphosphonates versus Denosumab on Risks of Cardiovascular Events in Patients with Type 2 Diabetes

(B13) Evaluation Suboptimal Outcomes in Crohn's Disease Patients with Biologic Treatment

(B14) Risk of Ischemic or Hemorrhagic Retinopathy and Anticholinergic Burden in Elderly Patient in Taiwan: A Case-Crossover Study

(B15) Use of Different Antihypertensive Drugs and Risk of Intradialytic Hypotension in Patients Undergoing Hemodialysis

(B16) Immunization Status of the 23-Valent Pneumococcal Polysaccharide Vaccine among Elderly Aged 65 and Older in South Korea

(B17) Comparison of biologic use in pivotal clinical trials vs. real-world setting with immune-mediated inflammatory diseases: an Italian population-based study from the VALORE project

(B18) Comparison of Serious Infections between Biosimilar and Bio-Originator Initiators in Canada: Population-Based Analyses

(B19) Disease severity profile and treatment switch patterns as treatment response proxy in Crohn’s disease population using Optum databases

(B20) Impact of COVID Lock-down on Adherence to Romosozumab Among US Post-menopausal Women Enrolled in Medicare

(B21) Joint pain in patients with atopic dermatitis receiving treatment with dupilumab in a nation-wide cohort study

(B23) Rates of Intraocular Inflammation Following Intravitreal Aflibercept Prefilled Syringe and Vial Injections in US Clinical Practice, 2014-2022

(B24) Risk of Venous Thromboembolism with Janus Kinase Inhibitors in Rheumatoid Arthritis: A Systematic Review

(B25) A Digital Toolkit to Contextualise and Visualise the Benefit and Risk of COVID-19 Vaccines in the European Union

(B26) Assessment of the U.S. Food and Drug Administration’s Risk Evaluation and Mitigation Strategy (REMS) for Prasugrel (Effient)

(B27) Communicating Drug Safety and Safe Use Conditions in Risk Evaluation and Mitigation Strategy Materials

(B28) Physician Knowledge of Safe Use of Cyproterone Acetate Monotherapies and Meningioma

(B29) The Use of Statins for the Primary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes: A Quantitative Benefit-Risk Analysis

(B30) Utility of Healthcare Professional (HCP) Surveys for Evaluating the Effectiveness of Additional Risk Minimization Measures (aRMMs): Experience from an HCP Survey Assessing the Effectiveness of aRMMs for Xeljanz® in Europe

(B31) What are patient with non-small cell lung cancer (NSCLC) preferences regarding treatment?

(B32) What do we know on patient preferences for treatment of multiple sclerosis?

(B34) Examining the risk of COVID-19 among cancer patients and comparing it with the Swedish general population: A register-based cohort study within the SCIFI-PEARL project

(B35) Glucagon Like Peptide-1 Receptor Agonists and the Risk of Skin Cancer Among Patients with Type 2 Diabetes: Population-Based Cohort Study

(B36) Predicting HER2 Status in Non-Small Cell Lung Cancer using Machine Learning Approach for Precision Cancer Pharmacoepidemiology in Large Databases

(B37) Predictive Biomarkers for PD-1/PD-L1 Checkpoint Inhibitor Response in NSCLC – an Analysis of Clinical Trial and Real-world Data

(B39) Trends in New and Persistent Opioid Use in Older Adults with Cancer

(B40) When does the clock start ticking? Deriving the date of cancer diagnosis from electronic health record data

(B41) A Framework for Considering Regulatory Likelihood of Acceptance of a Single-Arm Trial

(B42) A retrospective cohort study of Gaucher Disease Type 1 to describe sub-optimal responders to standard of care treatments in the United States

(B43) A systematic review of the efficacy of sirolimus and methotrexate after hematopoietic stem cell transplantation

(B44) Assessing Risk of Bias in Comparative Effectiveness Studies of Chimeric Antigen Receptor T-Cell Therapies for Relapsed or Refractory Large B-Cell Lymphoma

(B45) Feasibility of Assessing Comparative Long-Term Safety for Gene Therapy Products by Creating an External Control Arm using Real-World Data Sources

(B46) Maximising the use of real-world data from multiple sources to generate comprehensive evidence: insights from retrospective cohorts of allogeneic hematopoietic cell transplant recipients with adenovirus infection

(B47) Cardiovascular risk stratification in patients with type 2 diabetes

(B48) Causal forests vs Inverse probability weighting for addressing cluster-level confounding in medical device and surgical epidemiology: A simulation study

(B49) Comparative cardiovascular effectiveness of liraglutide 3 mg

(B50) Comparing approaches to achieving exact balance on key covariates in propensity score matched analyses: a simulation study

(B51) Immortal time bias arising from inappropriate anchor of outcome event date

(B52) Preventing Heart Failure Admissions with Sodium-Glucose Cotransporter-2 Inhibitors versus Angiotensin Receptor-Neprilysin Inhibitors: A Target Trial Emulation Study

(B53) Sulfonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: a population-based cohort study

(B54) Variance Estimation of the Risk Difference When Using Propensity-Score Matching and Weighting with Time-To-Event Outcomes

(C01) Agreement of COVID-19 Incidence Between the Authoritative Data and Real-World Evidence in England

(C02) Anonymized tokenization technology to link real world data and assess the potential for exposure misclassification for pharmacoepidemiology research

(C03) Contemporary pharmacoepidemiology practice for real world data source identification and feasibility assessment – Results from an ISPE-sponsored online survey

(C04) European Rare Disease Registries: A Collaborative Effort to Assess the Quality and Suitability of Registries to Describe the Natural History of Disease and Treatment Landscape of Spinal Muscular Atrophy

(C05) Phased Target Trial Design and Meta-Analysis in a Head-to-Head Treatment Comparison

(C06) The risk of incident dementia and Alzheimer’s disease after the use of centrally-acting versus non-centrally acting angiotensin-converting enzyme inhibitors: a target trial emulation study

(C08) Using Historical RCT Controls to Contextualize Necessity of Unblinding of Serious Adverse Events and Adverse Events of Special Interest – Conceptual Framework and Database Development

(C09) Diabetes medication use in digital hospitals in China: a cross-sectional descriptive study

(C10) Early identification of patients at risk for Type-2 diabetes using machine learning models

(C11) Effect of Mobile Applications on the Spontaneous Reporting of Adverse Drug Reactions: A Systematic Review and Individual Patient Data Meta-Analysis

(C12) Identification of Treatment-Resistant Major Depressive Disorder using a Machine Learning Algorithm

(C13) Machine learning (ML) model for prediction of pneumonitis using real-world data (RWD) on immune checkpoint inhibitor (ICI)-treated advanced non-small cell lung cancer (aNSCLC)

(C14) Switching codeine to a prescription-only drug successfully reduced public engagement: An exploratory analysis using Google Trends

(C15) Use of A Wearable Activity Tracker to Assess Differences in REM Sleep Duration Among Adolescents With and Without Depression

(C16) Wearables and digital tools for infectious disease: Overview of existing digital contact tracing systems

(C17) Do Enrollment Gaps Matter? A Real-World Study of Administrative Health Claims Gaps Using the Sentinel Common Data Model

(C18) Drug Utilization Patterns among Patients Hospitalized with COVID-19 in the United States, January 2021– February 2022

(C19) Opioid and benzodiazepine prescribing patterns for noncancer pain in primary care practices in Nova Scotia, Canada from 2011-2018

(C20) Patient characteristics and treatment patterns for migraine patients initiating erenumab in Denmark and Sweden

(C21) Paxlovid or Molnupiravir Post-Treatment Medication Use Evaluation of Rebound COVID-19

(C22) Plaque Psoriasis in the Real-World Setting: Disease Activity and Initiation of Advanced Therapy

(C23) Racial-Ethnic Differences in ADHD Diagnosis and Pharmacotherapy Among Adolescents and Emerging Adults in a US Commercial Healthcare Claims Database

(C24) Temporal Trends in Use of Old and New Intravenous Iron Formulations among US Medicare Beneficiaries, 2008-2019

(C25) A data mining approach for the discovery of potentially high- and low-risk high-order drug combinations from real world data

(C26) A Review of Existing Clinical Guideline Recommendations for Contraceptive Selection in Women with Epilepsy with a Focus on Drug-Drug Interactions

(C27) Concomitant use of selective serotonin reuptake inhibitors with oral anticoagulants and the risk of major bleeding in patients with atrial fibrillation

(C28) Evaluation of QT Prolongation Associated with Haloperidol Using KIDS-KAERS Database, 2016-2020

(C29) Network Analysis of Anticholinergic Medication Use in a Cohort of People Aging with HIV: Identification of Anticholinergic Medication Drivers of Physical Frailty States

(C30) Review of Case Reports and Analysis of VigiBase Data to Identify Potential Cannabis Natural-Product Drug Interactions

(C31) The effect of isoniazid use for tuberculosis prevention on pregnancy incidence among women living with HIV on antiretroviral treatment and progestin-based hormonal contraception

(C32) The Interaction Between Gliclazide and Omeprazole via CYP2C19 and the Risk of Hypoglycaemia: A Case-Crossover Study using Primary Care Data from the UK

(C33) Effects of PM2.5 Exposure and Anticoagulant Use on Bleeding Events in a High-Risk Medicare Cohort: Evidence of Drug - Air Pollution Interaction

(C34) Environmental burden and utilization of analgesics around Lake Mälaren, Sweden’s largest drinking water source

(C35) Geographical visualization of urinary Escherichia coli resistance in the Illawarra region, Australia

(C36) Human health risk assessment and meta-analysis of arsenic-contaminated drinking water in endemic regions of India

(C37) Changes in Comorbidity / Multimorbidity within 5 Years, Post-Recruitment into the UK Biobank

(C38) Effects of Genetic Polymorphism and Drug-Drug Interaction on Outcomes of Clopidogrel Treatment

(C39) Genetic polymorphism and risk of anti-tuberculosis drug-induced liver injury (ATDILI): a systematic review and meta-analysis

(C40) Implementing Mendelian randomization to assess foetal risk from intrauterine prescriptive drugs for the treatment of glycaemic conditions, hypertension and thyroidism in pregnancy

(C41) Individual and Interactive Effects of Three Common Polymorphisms in APOA1 Gene and Obesity on Lipid-lowering Efficacy of statin

(C42) Pharmacogenetic Testing in Switzerland: a Descriptive Study Using Swiss Claims Data

(C43) Sclerostin inhibition and cardiovascular risk: triangulating the evidence using Mendelian randomisation methods

(C44) Utilization of Drugs with Pharmacogenetic Dosing Recommendations in Children in Switzerland: a Descriptive Study Using Swiss Claims Data

(C45) Comparative safety of adding SNRIs versus NSAIDs to short-acting opioid for non-malignant pain in nursing homes

(C46) Evidence-based data for the use of newly approved medications in older adults: a descriptive analysis from clinical trials to product monographs

(C47) Heterogeneous Treatment Effects of Metformin on the Risk of Dementia in People with Type 2 Diabetes: A Longitudinal Observational Study

(C48) Incidence and prevalence of Parkinson’s disease and utilisation of antiparkinson treatments: a population-based cohort study

(C49) Potential inappropriate medication use among older patients with Parkinson’s disease: A cross sectional analysis of a national health insurance database in China

(C50) Redefining Polypharmacy in Older People Taking into Account Longitudinality: A Joint Latent Class Analysis

(C51) Statins discontinuation near the end of life: a retrospective cohort study using electronic health records

(C52) Validating Medicare claims-based algorithms for deprescribing of benzodiazepines using a novel linkage with electronic health records data